These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37301953)

  • 1. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.
    Jakubowski A; Fowler S; Fox AD
    Addict Sci Clin Pract; 2023 Jun; 18(1):40. PubMed ID: 37301953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "We'll be able to take care of ourselves" - A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs.
    Frost T; Deutsch S; Brown S; Lemien E; Cunningham CO; Fox AD
    Subst Abus; 2021; 42(4):983-989. PubMed ID: 33759722
    [No Abstract]   [Full Text] [Related]  

  • 3. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation.
    Jakubowski A; Rath C; Harocopos A; Wright M; Welch A; Kattan J; Navos Behrends C; Lopez-Castro T; Fox AD
    Harm Reduct J; 2022 Jul; 19(1):75. PubMed ID: 35818071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale.
    Perez-Correa A; Abbas B; Riback L; Ghiroli M; Norton B; Murphy S; Jakubowski A; Hayes BT; Cunningham CO; Fox AD
    Contemp Clin Trials; 2022 Mar; 114():106674. PubMed ID: 34990854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial.
    Watson DP; Swartz JA; Robison-Taylor L; Mackesy-Amiti ME; Erwin K; Gastala N; Jimenez AD; Staton MD; Messmer S
    BMC Public Health; 2021 Mar; 21(1):630. PubMed ID: 33789642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
    JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender disparities in opioid treatment progress in methadone versus counseling.
    Guerrero E; Amaro H; Kong Y; Khachikian T; Marsh JC
    Subst Abuse Treat Prev Policy; 2021 Jun; 16(1):52. PubMed ID: 34162420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Services for perinatal patients with opioid use disorder: a comprehensive Baltimore City-wide 2023 assessment.
    Ratner JA; Kirschner JH; Spencer B; Terplan M
    Addict Sci Clin Pract; 2024 Oct; 19(1):73. PubMed ID: 39407344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.
    Corneli A; Perry B; Des Marais A; Choi Y; Chen H; Lilly R; Ayers D; Bennett J; Kestner L; Meade CS; Sachdeva N; McKellar MS
    Harm Reduct J; 2022 Dec; 19(1):132. PubMed ID: 36463214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
    Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
    J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
    Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
    J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scoping review of interventions to link individuals to substance use services at discharge from jail.
    Grella CE; Ostlie E; Watson DP; Scott CK; Carnevale J; Dennis ML
    J Subst Abuse Treat; 2022 Jul; 138():108718. PubMed ID: 35012792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV; Levin FR; Reilly MP; El-Bassel N
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Provision of medications to treat opioid use disorder via a mobile health unit: A scoping review.
    Bailey A; DaCunha A; Napoleon SC; Kang AW; Kemo M; Martin RA
    J Subst Use Addict Treat; 2024 Sep; 164():209431. PubMed ID: 38852822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The estimated impact of state-level support for expanded delivery of substance use disorder treatment during the COVID-19 pandemic.
    Nesoff ED; Marziali ME; Martins SS
    Addiction; 2022 Jun; 117(6):1781-1786. PubMed ID: 34873783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.
    Andraka-Christou B; Saloner B; Gordon AJ; Totaram R; Randall-Kosich O; Golan M; Stein BD
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):492-503. PubMed ID: 35772010
    [No Abstract]   [Full Text] [Related]  

  • 20. Substance use disorder bridge clinics: models, evidence, and future directions.
    Taylor JL; Wakeman SE; Walley AY; Kehoe LG
    Addict Sci Clin Pract; 2023 Apr; 18(1):23. PubMed ID: 37055851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.